Printer Friendly

SCHERER'S FRENCH SUBSIDIARY PARTICIPATES IN FRENCH NATIONWIDE VITAMIN STUDY

 TROY, Mich., May 3 /PRNewswire/ -- R.P. Scherer Corporation (NYSE: SHR) announced today that its French subsidiary, R.P. Scherer S.A., has been selected to be the supplier of softgel capsules containing vitamins and anti-oxidants as well as placebos for the first phase of a study being conducted by the National Institute for Medical Research in France. This study will attempt to ascertain if a supplement of vitamin C and E, beta-carotene, as well as zinc and selenium, at a dose that does not pose any danger to the volunteers, would be able to prevent certain cancers and heart disease.
 The study will take eight years, with 15,000 volunteers comprised of men aged 45 to 60 and women aged 35 to 60, with the composition of the group reflecting as closely as possible the composition of the French population. These 15,000 people will be followed very closely during the eight-year period with regular questioning of their diet, health problems and by providing thorough annual check-ups free of charge, the results of which will be given to the subject's doctor. Any suspicion of cancer or cardiovascular disease will be followed up with more detailed analysis, permitting detection of disease very quickly.
 A critical element of the study is to employ vitamin and mineral supplements at far smaller doses than what can be currently obtained in the market. The objective is to determine if doses at a nutritional rather than medical level demonstrate efficacy in terms of preventing cancer or cardiovascular disease. The national coordinator of the study, Dr. Hercberg, stated "If the nutritional supplement turns out to be effective before the end of the study, it is possible we will stop the research and propose such a supplement to the control patients taking the placebo."
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(R), ZYDIS(R) and PULSINCAP(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The company operates a global network of 15 facilities in 11 countries.
 -0- 5/3/93
 /CONTACT: Nicole Williams, executive vice president & CFO, R.P. Scherer, 313-649-0900/
 (SHR)


CO: R.P. Scherer Corporation; R.P. Scherer S.A. ST: Michigan IN: MTC HEA SU:

JG -- DE008 -- 3663 05/03/93 10:09 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:415
Previous Article:SOUTHERN BELL EXPECTS TO PROCESS 85 MILLION MOTHER'S DAY CALLS
Next Article:WORLD SATELLITE NETWORK
Topics:


Related Articles
R.P. SCHERER SIGNS AGREEMENT WITH PIERRE FABRE
FRENCH MINISTRY ISSUES STATEMENT REGARDING RHONE-POULENC
R.P. SCHERER ANNOUNCES ACQUISITION IN SPAIN
SCHERER ANNOUNCES CREATION OF NEW DEVELOPMENT GROUP
R.P. SCHERER ANNOUNCES CAPACITY EXPANSION
PROCYTE REJECTS UNSOLICITED MERGER PROPOSAL
Elan and Scherer Announce License for Zydis Formulation
R.P. Scherer Announces Agreement with GlaxoWellcome.
Ex R.P. Scherer Chairman and Chief Executive Officer, Alex Erdeljan joins board of Eurand.
R.P. Scherer. (Patent News).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters